title: High-dose intravenous methylprednisolone therapy associated with osteonecrosis in patients with systemic lupus erythematosus.
abstract: Osteonecrosis is related to the use of steroids in patients with systemic lupus erythematosus (SLE); its association with the use of 'pulses' of methylprednisolone (PMP) is not clear at present. In a retrospective analysis of 190 patients with SLE we found that 19% of 36 patients treated with PMP had osteonecrosis compared with 6% of 154 patients without that treatment (P < 0.04). Risk factors associated with osteonecrosis were PMP treatment, cushingoid appearance, steroid doses > or = 40 mg/day during the first month of treatment, a ratio of steroid dose in grams/year > or = 12, hematuria and proteinuria. In a stepwise regression model, when cushingoid appearance was excluded, PMP became the only significant factor (P = 0.045). We conclude that osteonecrosis can be considered a long-term complication of PMP treatment in SLE patients.
authors.affiliation: Servicio de Medicina, Hospital Dr Sótero del Río, Santiago, Chile.
authors.forename: L
authors.initials: L
authors.lastname: Massardo
authors.forename: S
authors.initials: S
authors.lastname: Jacobelli
authors.forename: M
authors.initials: M
authors.lastname: Leissner
authors.forename: M
authors.initials: M
authors.lastname: González
authors.forename: L
authors.initials: L
authors.lastname: Villarroel
authors.forename: S
authors.initials: S
authors.lastname: Rivero
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D005260:Female; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000150:complications / Q000188:drug therapy*; D008297:Male; D008775:Methylprednisolone / Q000008:administration & dosage / Q000009:adverse effects*; D008875:Middle Aged; D010020:Osteonecrosis / Q000139:chemically induced*; D012189:Retrospective Studies
chemical_list: D008775:Methylprednisolone